ArrowMark Colorado Holdings’s Dyne Therapeutics DYN Stock Holding History

ArrowMark Colorado Holdings’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.2M	Sell	673,949 -26,704	-4%	-$460K	0.32%	92
2025 Q4	$13.7M	Sell	700,653 -85,262	-11%	-$1.61M	0.3%	99
2025 Q3	$9.94M	Buy	785,915 +15,690	+2%	+$179K	0.18%	136
2025 Q2	$7.33M	Sell	770,225 -127,721	-14%	-$1.41M	0.13%	159
2025 Q1	$9.39M	Sell	897,946 -34,285	-4%	-$490K	0.15%	130
2024 Q4	$22M	Buy	932,231 +32,041	+4%	+$948K	0.3%	89
2024 Q3	$32.3M	Sell	900,190 -19,226	-2%	-$765K	0.41%	69
2024 Q2	$32.4M	Buy	919,416 +537,000	+140%	+$15.6M	0.39%	73
2024 Q1	$10.9M	Hold	382,416	–	–	0.12%	137
2023 Q4	$5.09M	Hold	382,416	–	–	0.06%	203
2023 Q3	$3.43M	Hold	382,416	–	–	0.04%	210
2023 Q2	$4.3M	Buy	382,416 +107,252	+39%	+$1.27M	0.05%	207
2023 Q1	$3.17M	Hold	275,164	–	–	0.04%	214
2022 Q4	$3.19M	Hold	275,164	–	–	0.04%	216
2022 Q3	$3.5M	Buy	275,164 +106,664	+63%	+$1.22M	0.04%	232
2022 Q2	$1.16M	Hold	168,500	–	–	0.01%	262
2022 Q1	$1.62M	Hold	168,500	–	–	0.01%	275
2021 Q4	$2M	Hold	168,500	–	–	0.02%	269
2021 Q3	$2.74M	Hold	168,500	–	–	0.02%	273
2021 Q2	$3.54M	Buy	168,500 +68,500	+69%	+$1.29M	0.03%	257
2021 Q1	$1.55M	Hold	100,000	–	–	0.01%	289
2020 Q4	$2.1M	Sell	100,000 -100,000	-50%	-$1.98M	0.02%	263
2020 Q3	$4.04M	Buy	+200,000	New	+$4.39M	0.04%	229

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

ArrowMark Colorado Holdings's DYN Position: Q1 2026 in Review

ArrowMark Colorado Holdings reduced its Dyne Therapeutics (DYN) stake by 3.8% in Q1 2026, selling an estimated $460K and leaving 673,949 shares worth $12.2M. The position accounts for 0.32% of the portfolio, ranked #92.

ArrowMark Colorado Holdings first reported a position in DYN in Q3 2020 and has held it in 23 quarters since. The position peaked at $32.4M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

ArrowMark Colorado Holdings held 673,949 shares of Dyne Therapeutics worth $12.2M as of Q1 2026.
ArrowMark Colorado Holdings sold 26,704 Dyne Therapeutics shares in Q1 2026, an estimated $460K.
Dyne Therapeutics made up 0.32% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #92 holding.
ArrowMark Colorado Holdings first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 23 quarters since.
ArrowMark Colorado Holdings's Dyne Therapeutics position peaked at $32.4M in Q2 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.